Burning Rock Biotech Ltd
Business
Burning Rock Biotech Ltd provides next-generation sequencing (NGS)-based cancer diagnostics, therapy selection and early cancer detection technologies. It offers a broad portfolio of NGS tissue and liquid biopsy tests (including OncoCompass™, OncoScreen™, OncoCompass™ Target), a personalized MRD test (CanCatch®), the multi-cancer early detection test OverC™, reagent kits, an automated library preparation system (Magnis BR) and data analysis tools. The business operates through two principal segments: a central laboratory service model and an in-hospital turnkey model, supported by R&D, manufacturing and CDx collaborations. Its products are distributed primarily across China’s hospital network and via central lab sample shipments, and it engages with pharmaceutical partners and holds international and domestic regulatory certifications enabling external collaborations.
Summary from filing dated 2025-04-29
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $77.16M |
| Net income | $-7.92M |
| Total assets | $117.31M |
| Total liabilities | $40.77M |
| Stockholders' equity | $76.54M |
| Operating cash flow | $-4.07M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Burning Rock Biotech Ltd's CIK number?
Burning Rock Biotech Ltd's SEC CIK number is 0001792267 (1792267). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Burning Rock Biotech Ltd's SEC filings?
All of Burning Rock Biotech Ltd's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.